Sun Pharma has entered into a research agreement with Israel’s Weizmann Institute of Science and Spain’s Health Research Institute of Santiago de Compostela to develop products for treating neurological diseases such as brain stroke and glioblastoma, a lethal brain cancer, according to a company statement.
Scientists at Weizmann have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma. Further studies of this enzyme will be conducted at the Health Research Institute in Spain. This enzyme may potentially be indicated for uses beyond these two brain diseases. Sun Pharma will have the first right to develop these “additional indications,” according the statement. Sun Pharma will have the exclusive option to conduct further development of the enzyme after completion of the preclinical studies. The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme. “As per the signed tripartite agreement, Sun Pharma will have the first right to develop these additional indications,” the ompany said.
